Guardant Health

173 articles with Guardant Health

• 

  Guardant Health and Foundation Medicine Face Off in Another Legal Battle

  11/25/2020

  Guardant Health is taking Roche-owned Foundation Medicine to court over a patent dispute for their liquid biopsy technology, further heating up the rivalry between the two cancer detection companies.

• Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering

  11/17/2020

  Guardant Health, Inc. announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering - Nov 16, 2020

  11/16/2020

  Guardant Health, Inc. announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

• Guardant Health Reports Third Quarter 2020 Financial Results

  11/5/2020

  Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, reported financial results for the quarter ended September 30, 2020.

• Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

  10/15/2020

  Guardant Health, Inc. announced the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which were sold by SoftBank Investment Advisers.

• Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder

  10/7/2020

  Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share,

• Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder

  10/6/2020

  Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers

• Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference

  9/1/2020

  Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

• Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test

  8/24/2020

  COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University

• Guardant Health to Participate in Upcoming August Investor Conferences

  8/10/2020

  Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences.

• Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

  8/7/2020

  Guardant Health, Inc. announces that the U.S. Food and Drug Administration has approved Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with any solid malignant neoplasm.

• Guardant Health Reports Second Quarter 2020 Financial Results

  8/6/2020

  Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, reported financial results for the quarter ended June 30, 2020.

• Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast Cancer

  7/30/2020

  Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an investigational selective estrogen receptor degrader (SERD) being studied in the treatment of advanced ER-positive,

• Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020

  7/21/2020

  Guardant Health, Inc. announced it will report financial results for the second quarter 2020 after market close on Thursday, August 6, 2020.

• Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic

  7/8/2020

  Guardant Health, Inc. announced a strategic collaboration with Janssen Biotech, Inc. to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer.

• Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug DevelopmentRepresents a large-scale liquid biopsy dataset of advanced cancer patients

  6/23/2020

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM ™  platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. The GuardantINFORM platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partne

• Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal CancerResults from a new patient cohort consistent with previously reported data

  6/22/2020

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).

• Guardant Health Appoints Vijaya Gadde to its Board of Directors

  6/16/2020

  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Vijaya Gadde to serve on its Board of Directors.

• Guardant Health Announces Full Exercise of Option and Closing of Public Offering

  6/8/2020

  Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today announced the closing of an underwritten public offering of 13,225,000 shares of its common stock at a public offering price of $84.00 per share,

• Guardant Health Announces Proposed Public Offering of Common Stock - Jun 01, 2020

  6/1/2020

  Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced the commencement of a proposed underwritten public offering of 10,000,000 shares of its common stock.